Log in

NASDAQ:CBLICleveland BioLabs Institutional Ownership

$2.24
0.00 (0.00 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.21
Now: $2.24
$2.42
50-Day Range
$1.52
MA: $2.02
$4.26
52-Week Range
$0.50
Now: $2.24
$5.00
Volume525,800 shs
Average Volume3.52 million shs
Market Capitalization$25.54 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95

Institutional Ownership

Institutional Ownership Changes (13F Filings) for Cleveland BioLabs (NASDAQ:CBLI)

Institutional Ownership Percentage: 3.58%

Institutional Buying and Selling by Quarter


Cleveland BioLabs (NASDAQ CBLI) Institutional Buying and Selling

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in Company
8/14/2019Vanguard Group Inc.52,874$77K0.0%-50.4%0.468%
2/13/2018Renaissance Technologies LLC241,016$0.97M0.0%+11.1%2.137%
8/11/2017Virtu KCG Holdings LLC52,091$0.15M0.0%+275.9%0.462%
5/16/2016Ladenburg Thalmann Financial Services Inc.38,843$0.13M0.0%-0.1%0.359%
(Data available from 1/1/2016 forward)
This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.